NCT01585181View on ClinicalTrials.gov

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

January 31, 2013

Conditions
Cholera
Interventions
BIOLOGICAL

PXVX0200

Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension

BIOLOGICAL

Placebo

Approx 2 grams of lactose reconstituted in water

Trial Locations (2)

21201

University of Maryland, Baltimore

40536-0084

University of Kentucky, Lexington

Sponsors

Lead Sponsor

Bavarian Nordic

Collaborators (1)

Emergent BioSolutions
All Listed Sponsors
collaborator

Emergent BioSolutions

INDUSTRY

lead

Bavarian Nordic

INDUSTRY